摘要
The replication licensing factors strictly regulate the DNA replication origin licensing process to guarantee the stability of the genome. Numerous experimental studies have recently demonstrated that the replication licensing factors as oncogenes are essential for the occurrence and development of cancers. Drug resistance, being one of the main characteristics of cancer stem cells, can cause a high recurrence rate and a low survival rate in patients with different cancers. However, the function of the replication licensing factors in cancer stemness remains unclear. The following article highlights the most recent research on DNA replication origin licensing factors in cancer and their function in anti-cancer drug resistance. Moreover, this article proposes a new perspective that replication licensing factors as chemotherapy shield affect anti-cancer drug resistance by promoting the stemness of cancer cells.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 1211-1219 |
| 页数 | 9 |
| 期刊 | International Journal of Biological Sciences |
| 卷 | 18 |
| 期 | 3 |
| DOI | |
| 出版状态 | 已出版 - 2022 |
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
学术指纹
探究 'DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver